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Background: Colorectal carcinomas spread easily to nearby tissues around the colon or rectum, and display strong
potential for invasion and metastasis. CSE1L, the chromosome segregation 1-like protein, is implicated in cancer
progression and is located in both the cytoplasm and nuclei of tumor cells. We investigated the prognostic
significance of cytoplasmic vs. nuclear CSE1L expression in colorectal cancer.
Methods: The invasion- and metastasis-stimulating activities of CSE1L were studied by in vitro invasion and animal
experiments. CSE1L expression in colorectal cancer was assayed by immunohistochemistry, with tissue microarray
consisting of 128 surgically resected specimens; and scored using a semiquantitative method. The correlations
between CSE1L expression and clinicopathological parameters were analyzed.
Results: CSE1L overexpression was associated with increased invasiveness and metastasis of cancer cells.
Non-neoplastic colorectal glands showed minimal CSE1L staining, whereas most colorectal carcinomas (99.2%,
127/128) were significantly positive for CSE1L staining. Cytoplasmic CSE1L was associated with cancer stage
(P=0.003) and depth of tumor penetration (P=0.007). Cytoplasmic CSE1L expression also correlated with lymph
node metastasis of the disease in Cox regression analysis
Conclusions: CSE1L regulates the invasiveness and metastasis of cancer cells, and immunohistochemical analysis
of cytoplasmic CSE1L in colorectal tumors may provide a useful aid to prognosis.
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Colorectal cancer (CRC) shows a high rate of metasta-
sis and is one of the most lethal cancers worldwide.
Metastasis, especially occult metastasis, contributes
considerably to the challenge of defining the prognosis
for a patient with this disease. Approximately 60% of
patients who undergo curative resection experience* Correspondence: chunchao@tmu.edu.tw
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reproduction in any medium, provided the orlocal recurrence or distant metastases [1]. The primary
treatment of CRC is surgical resection of the primary
tumor and possibly the regional lymph nodes; this may
be combined with chemotherapy, depending on the
depth of tumor penetration and the disease stage [2].
The development and progression of a tumor is con-
trolled by oncogenes and tumor suppressor genes.
Alterations in the expression of any of these genes in
a tumor may correlate with the clinical-pathological
characteristics and behavior of CRC. Thus, examin-
ation of these gene expressions may be useful for
prognosis of the disease.
Chromosome segregation 1-like protein (CSE1L) is the
human homologue of CSE1, the yeast chromosome seg-
regation protein [3]. CSE1L is highly expressed in mostThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with cancer progression [4-12]. CSE1L is located in both
the cytoplasm and the nuclei of cells. Nuclear CSE1L
regulates the transcriptional activity of the p53 protein, a
major tumor suppressor protein [13,14]. Cytoplasmic
CSE1L is associated with microtubules; this association
has been shown to stimulate the extension of invadopo-
dia (invasive feet) and to enhance the migration of
tumor cells [15]. Therefore, both nuclear and cytoplas-
mic CSE1L are implicated in cancer progression. We
analyzed the relationships between CSE1L cytoplasmic/
nuclear distribution and the clinical-pathological charac-
teristics of CRC. The findings showed that high CSE1L
cytoplasmic expression was associated with the depth of
tumor penetration and disease stage. We concluded that
cytoplasmic CSE1L plays a role in the invasion and me-
tastasis of CRC; furthermore, immunohistochemical ana-
lysis of CSE1L distribution in a tumor provides a useful
ancillary tool for the prognosis of CRC.
Methods
Cells, Vectors, and DNA Transfection
B16F10 melanoma cells and COLO 205 colon cancer
cells were obtained from the American Type Culture
Collection (Manassas, VA, USA). The human HT-29
colon cancer cells transfected with vectors expressing
CSE1L (i.e. the HT-29-CSE1L cells) and HT-29 cells
transfected with the empty vectors (i.e. the HT-29-EV
cells) were established previously [16]. Cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% heat-inactivated fetal bovine
serum (FBS), 100 units/mL of penicillin, 100 mg/mL of
streptomycin, and 2 mmol/L of glutamate at 37°C under
a humidified 5% CO2 atmosphere. B16F10 cells and
COLO 205 cells were separately transfected with
pcDNA-CSE1L [16], a eukaryotic expression vector cap-
able of expressing CSE1L, using the Lipofectamine plus
reagent (Invitrogen, Carlsbad, CA, USA). Transfected
cells were selected with G418 for 3 wk. Multiple drug-
resistant colonies (>100) were pooled and amplified in
mass culture. The transfected cells were maintained in
media containing 200 mg/mL of G418; for the experi-
ments, cells were cultured in medium without G418.
Western blotting
Cells were harvested using a rubber policeman and
were washed with ice-cold phosphate buffered saline
(PBS). They were then lysed in an ice-cold radioim-
munoprecipitation assay (RIPA) buffer (25 mM Tris-
HC1, pH 7.2, 0.1% sodium dodecyl sulfate [SDS], 0.1%
Triton X-100, 1% sodium deoxycholate, 150 mM
NaC1, 1 mM ethylenediaminetetraacetic acid [EDTA],
1 mM sodium orthovanadate, 1 mM phenylmethane-
sulfonyl fluoride, 10 μg/mL aprotinin, and 5 μg/mlleupeptin). Protein concentration was determined using a
BCA protein assay kit (Pierce, Rockford, IL, USA). Samples
were resolved with SDS-polyacrylamide gel electrophoresis.
Proteins were transferred to nitrocellulose membranes
(Amersham Pharmacia, Buckinghamshire, UK), and
immunoblotting was performed by enhanced chemilu-
minescence (ECL) using an ECL Plus Western Blot-
ting Detection System (GE Healthcare, Little Chalfont,
Buckinghamshire, UK) with the anti-CSE1L (clone 24) anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Levels of β-actin were assayed with anti-β-actin (Ab-5)
(Lab Vision, Fremont, CA, USA) for loading control.
In vitro invasion assay
Polyvinylpyrrolidone-free polycarbonate filters, size 8 μm
(Costar, Cambridge, MA, USA), were soaked in matrigel
(1:5 in DMEM; BD Biosciences, Cockeysville, MD, USA)
at 4°C for 36 h. The filters were then incubated at 37°C
for 2 h, before being washed with DMEM and placed in
microchemotaxis chambers. Cells were treated by 0.1%
trypsin-EDTA digestion, resuspended in DMEM contain-
ing 10% FBS, and then washed with serum-free DMEM.
Finally, cells (1 × 105) were suspended in DMEM (200 μl)
and placed in the upper compartment of the chemotaxis
chambers. Culture medium (300 μl) containing 20% FBS
was placed in the lower compartment of the chemotaxis
chambers to serve as a source of chemoattractants. After
incubation for 6 h (for the vector-transfected B16F10
cells) and 24 h (for the vector-transfected COLO 205
cells) at 37°C, cells on the upper surface of the filters
were completely wiped away with a cotton swab. Cells on
the lower surface of the filters were fixed in methanol,
stained with hematoxylin and eosin, and then counted
under a microscope. Cells invaded to the microchemo-
taxis chambers were also counted. The assays were
repeated 3 times, and each assay consisted of 4 replicate
filters for each cell line. For each replicate, the number of
migrated tumor cells in 10 randomly selected fields was
determined, and the counts were averaged.
Animal metastasis models
We purchased C57BL/6 mice aged 6 to 7 weeks old (Na-
tional Laboratory Animal Center, Taipei, Taiwan) and
housed them in an animal holding room under standard
conditions (22°C; 50% humidity; 12-h light/dark cycle).
Each mouse was injected in the tail vein with viable cells
(3 × 104 cells in 100 μl PBS/mouse). The experiment
included 11 and 14 mice injected with B16-EV and B16-
CSE1L cells, respectively. Three weeks after injection,
the mice were sacrificed and necropsied. The numbers
of tumors in their lungs were counted using macrogra-
phy and micrography.
For the animal liver metastasis model, NOD SCID
mice (age range 6 to 7 weeks old; National Laboratory
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above. The experiment included eight mice injected with
HT-29-EV cells and eight mice injected with HT-29-
CSE1L cells. Mice were anesthetized using isofluorane, a
small abdominal flank incision was created and the
spleen was exteriorized. HT-29-EV or HT-29-CSE1L
cells (3 × 106 cells in 100 μl PBS/mouse) were injected
into the spleen with a 27-gage needle, and the spleen
was returned to the abdomen and the wound was
closed. Three weeks after injection, mice were sacri-
ficed. A complete autopsy with inspection of the liver,
lung, kidneys, intestine, and spleen for macroscopically
visible tumors was performed. Suspicious tissue lesions
were examined histopathologically. Mouse care and ex-
perimental procedures were performed following the
guideline of the Animal Care Committee of Academia
Sinica, Taiwan.
Patients
CRC samples were obtained from 128 consecutive
human patients who had recently received a diagnosis at
our hospital. The study protocol was approved by the
Ethics Committee of the Taipei Medical University Hos-
pital, Taipei, Taiwan. All participants had the study
explained to them and gave informed consent by using
institutional review board-approved guidelines before
any participation in accordance with the guidelines
approved by the institutional review board. The study
group included 76 men and 52 women. The mean age of
the patients was 64.3 years (range, 28 to 93 y). Tumor
staging, grading, and categorization followed the 7th edi-
tion of the Cancer Staging Manual of the American Joint
Committee on Cancer [17] and the 7th edition of the
TNM Classification of Malignant Tumours [18]. In these
systems, a grade 1 tumor is defined as well-differen-
tiated, grade 2 is moderately differentiated, and grade 3
is a poorly differentiated tumor.
Immunohistochemical tissue microarray
Three tissue cores from cancerous tissue and one tissue
core from non-cancerous tissue in each paraffin block
was longitudinally cut and arranged into new paraffin
blocks to generate tissue microarrays. The manual
method of the BiosynMatric Handmade Kit (Formosa
Transcrip, Kaohsiung, Taiwan) was used. The tissue sec-
tions were stained with hematoxylin and eosin to con-
firm the presence of morphologically representative
areas of the original cancers.
The paraffin-embedded CRC specimens and paired
non-tumorous tissue sections (4 μm) were deparaffinized
in xylene and rehydrated in graded alcohol. Antigen re-
trieval was performed by treatment with a boiling citrate
buffer (10 mmol/L, pH 6.0) for 20 min. Endogenous per-
oxidase activity was blocked using 3% hydrogen peroxidein water, and nonspecific staining was blocked by incu-
bation with 5% bovine serum albumin in PBS for 1 h at
room temperature. The samples were incubated with an
100-fold dilution of anti-CSE1L antibody (clone 3D8,
Abnova, Taipei, Taiwan) for 20 min at room temperature
and were then washed 3 times with PBS; thereafter, the
slides were incubated with a horseradish peroxidase/Fab
polymer conjugate for another 30 min. The sites of per-
oxidase activity were visualized using diaminobenzidine
(3, 30-diaminobenzidine tetrahydrochloride) as the sub-
strate and were counterstained using Mayer’s hematoxylin.
In the negative control, the primary antibody was omitted
and replaced by PBS. CRC tissues are known to be positive
for CSE1L staining [12]; thus, no positive control was used
in this study.
Immunohistochemical scoring system
The results of CSE1L immunohistochemical staining
were analyzed using a semiquantitative scoring system.
The system combined the percentage of immunoreactive
cells (quantity score) and an estimate of staining inten-
sity (staining intensity score). Each tumor was scored
according to the quantity and intensity of the nuclear or
cytoplasmic staining, with the rating being confirmed by
2 expert pathologists. The proportion of cells stained
was recorded as a percentage, and the intensity score
was based on a scale of 0 to 3: 0, no staining; 1, weak
staining; 2, moderate staining; and 3, strong staining.
The total possible intensity score was 300, calculated as
follows: (0 × percentage unstained) + (1 × percentage of
weak staining) + (2 × percentage of moderate staining) +
(3 × percentage of strong staining). We subdivided the
CSE1L immunohistological staining results into low-
CSE1L (CSE1L staining 0 and 1+) and high-CSE1L
(CSE1L staining 2+ and 3+) subgroups.
Statistical analysis
The between-groups differences for the clinicopathologic
variables were assessed using the Fisher exact test. The
prognostic ability of each variable was evaluated, includ-
ing nuclear and cytoplasmic expressions of CSE1L,
tumor grade, clinical stage, T status, and lymph node
metastasis. The primary outcome was overall patient
survival, which was defined as the time from surgery to
death because of the disease, or to the date of the final
follow-up. Disease-related death was confirmed by aut-
opsy and imaging (computerized tomography and/or
magnetic resonance imaging). Univariate analysis for
overall survival used the Cox proportional hazards
model and estimates of hazard ratios, and P values were
adjusted for multiple significance. The distribution of
overall survival was estimated using Kaplan-Meier ana-
lysis and log-rank tests. All analyses were performed
using the Statistical Package for Social Sciences (SPSS)
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less than 0.05 (for a two-tailed test) was considered sta-
tistically significant.
Results
CSE1L overexpression increased invasion of colorectal
cancer cells
We studied the effect of CSE1L expression on the inva-
sion and metastasis of tumor cells. Previous studies have
reported that malignant melanoma is a frequent source
of metastasis to the gastrointestinal tract, including the
colon [19]. The B16F10 melanoma cell line is widely
used as a model for studying numerous aspects of can-
cer biology, including metastasis [20]. We used B16F10
melanoma cells and COLO 205 human colon cancerFigure 1 Increased CSE1L expression enhanced the invasiveness and
EV, B16-CSE1L, COLO-EV, and COLO-CSE1L cells were assayed by immunob
control. The invasive ability of the cells was analyzed by in vitro invasion as
Methods”. (B) Animal models showed that CSE1L regulated the metastasis
photograph of pulmonary tumors in C57BL/6 mice injected with B16-EV an
regulated the hepatic metastasis of HT-29 colon cancer cells in nude mice.
injected with HT-29-CSE1L cells. One mouse injected with HT-29-CSE1L cel
tumors in the livers of SCID mice were examined 21 days after injection.cells to study the invasion- and metastasis-stimulating
activities of CSE1L in cancer. The B16F10 cells and
COLO 205 cells were transfected with the control
pcDNA empty vectors and the pcDNA-CSE1L vectors to
yield B16-EV, B16-CSE1L, COLO-EV, and COLO-
CSE1L cells, respectively (Figure 1A). Matrigel-based in-
vasion assay showed that CSE1L overexpression was
associated with increased in vitro invasiveness of B16F10
melanoma cells and COLO 205 colon cancer cells
(Figure 1A). The cell count for invaded cells per field
was 109.4 ± 12.6 (mean ± SD) for B16-EV cells and
406.8 ± 23.9 for B16-CSE1L cells. For COLO-EV and
COLO-CSE1L cells, the count for invaded cells was 59.5 ±
15.2 and 222.5 ± 91.8, respectively. The animal-model
study showed that CSE1L overexpression was associatedmetastasis of cancer cells. (A) The levels of CSE1L expression in B16-
lotting with anti-CSE1L antibody. The β-actin levels were assayed as a
says using chemotaxis chambers, as described in “Materials and
of B16F10 cancer cells. The upper figure is a representative
d B16-CSE1L cells. (C) In vivo metastasis study showed that CSE1L
Eight mice were injected with HT-29-EV cells and eight mice were
ls died 3 days after injection was excluded from the study. Metastatic
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B16F10 melanoma cells. CSE1L overexpresion increased
the tumor pulmonary metastasis of the B16F10 melanoma
cells in C57BL/6 mice by 100% (P=0.01) (Figure 1B). The
lung tumors were 13.7 ± 4.8 (mean ± SD, tumors per
mouse) and 47 ± 15.8 for mice injected with B16-EV and
B16-CSE1L cells, respectively.
In vivo metastasis experiments using human colon
cancer cells overexpressing CSE1L were also performed
to study the association between CSE1L expressing and
the metastasis of colorectal cells to the liver, the main
target organ for colorectal cancer. Injection of colorec-
tal tumor cells directly into the spleen of nude mice
has been reported to be a suitable animal model system
to study colorectal tumor-cell metastasis [21]. The
Colo 205 human colon cancer cells are reported to be
unable to metastasize to the lung or liver of nude
mice after intrasplenic injections in the colorectal
tumor-cell metastasis experiments [21], thus we used
the HT-29 human colon cancer cells to study the
colorectal tumor in vivo metastasis experiments. SCIDFigure 2 CSE1L expression in non-tumorous colorectal glands and cy
Representative immunohistochemical images showed very low (±) CSE1L s
cytoplasmic staining in colorectal carcinoma displaying low (C, D) or high
F, 400×.mice were intrasplenically injected with HT-29 cancer
cells transfected with vectors expressing CSE1L (i.e.
the HT-29-CSE1L cells) or HT-29 cancer cells trans-
fected with the empty vectors (i.e. the HT-29-EV cells)
[16]. Tumors in mice were examined and counted 21
days after injection. The proliferation rate of HT-29-
CSE1L cells was slower than that of HT-29-EV cells
due to the induction of cell polarity by CSE1L in HT-
29 cells [16]. Nevertheless, our data showed that
enhanced CSE1L expression increased the metastasis
of HT-29 colon cancer cells to the livers of the mice,
although obviously the tumor lesions were bigger in
liver tumors induced by HT-29-EV cells than that
induced by HT-29-CSE1L cells (Figure 1C). Liver me-
tastasis were assayed in 71.4% (5/7) of mice injected
with HT-29-CSE1L cancer cells, and were assayed in
50.0% (4/8) of mice injected with HT-29-EV cancer
cells. No metastasis of the tumor cells to other
organs was observed. The results indicate that CSE1L
plays a role in regulating the metastasis of colorectal
cancer cells.toplasmic CSE1L expression in colorectal carcinomas. (A, B)
taining in nonneoplastic colorectal glands. (C-F) Results for CSE1L
(E, F) staining. Original magnification: A, C, and E, 100×; B, D, and
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and cytoplasmic CSE1L was associated with T status and
tumor stage
Colorectal glands are important functional organs in
colorectal tissue and are also the origin of colorectal car-
cinomas [22]. We performed immunohistochemistry
analysis with tissue microarray consists of 128 colorectal
tumors and normal marginal tissues. The results showed
that the non-neoplastic colorectal glands typically dis-
played very low (±) CSE1L staining (Figure 2). By con-
trast, most colorectal carcinomas (99.2%, 127/128) were
significantly positive (1+ to 3+) for CSE1L staining, with
both the cytoplasm and nuclei of tumor cells typically
showing a positive stain (Figures 2 and 3). These results
suggested that the use of immunohistochemical analysis
of CSE1L expression in colorectal glands might be valu-
able in diagnosing CRC.
Expression of CSE1L in non-neoplastic colorectal
glands was used as an internal control and provided a
scoring baseline for CSE1L staining in colorectal tumors.
The immunohistochemical data were analyzed using a
semiquantitative scoring system for the quantity and in-
tensity of nuclear or cytoplasmic CSE1L staining. Two
subgroups were classified: high staining (2+ and 3+) and
low staining (0 and 1+) (Figures 2 and 3). For cytoplas-
mic CSE1L staining, 63 cases displayed low staining
(49.2%, 63/128), and 65 cases showed high staining
(50.8%, 65/128) (Table 1). For nuclear CSE1L immunoreac-
tivity, 70 cases displayed low staining (54.7%, 70/128) and
58 showed high staining (45.3%, 58/128) (Table 2). The
associations between CSE1L immunohistochemical stain-
ing (cytoplasmic and nuclear) and the clinical parametersFigure 3 Representative immunohistochemical images of nuclear CSE
classified as low-CSE1L nuclear staining (A, B) or high-CSE1L nuclear staininwere analyzed, and the results are shown in Tables 1 and 2.
The clinical parameters included tumor grade, T status,
stage, lymph node metastasis, and overall survival.
Statistical analysis showed that high-CSE1L cytoplas-
mic staining in a CRC tumor was associated with
advanced cancer stage (Stage II, III, or IV) and depth of
tumor penetration (T status) (Table 1). No statistically
significant relationship was noted between nuclear
CSE1L staining and clinical manifestations, including
tumor stage (Table 2). Analysis of the survival data
showed that high cytoplasmic CSE1L staining in colorec-
tal tumors was associated with a relatively poor overall
patient survival rate, compared with cases displaying low
staining (Figure 4). The median survival rate of cases dis-
playing high cytoplasmic CSE1L expression was 42.0 mo,
whereas in cases with low expression it was 51.6 mo. Simi-
larly, the mean survival rate was 54.0 mo and 64.8 mo,
respectively, for cases with high and low cytoplasmic
CSE1L expression. For nuclear CSE1L expression, the
median survival time for cases displaying high expression
was 40.8 mo, compared with 44.4 mo for low expres-
sion. The mean survival rate was 56.4 mo and 61.2 mo,
respectively, for high and low nuclear CSE1L expression
cases. The Cox proportional hazards model (univariate
analysis) showed that for patients with high cytoplasmic
CSE1L expression, survival was significantly associated
with tumor size, lymph node metastasis, and TNM stage
(Table 3).
Discussion
The diagnosis and prognosis of CRC may be challenging
at times. Although patients with stage I tumors usually1L staining in colorectal carcinoma. Colorectal tumor samples were
g (C, D). Original magnification: A and C, 100×; B and D, 400×.
Table 1 Tumor cytoplasmic CSE1L expression and clinical
parameters in CRC
Cytoplasmic CSE1L Total P
Low (1+) High (2+ or 3+)
Sex
female 26 (50)# 26 (50) 52 0.884
male 37 (48.7) 39 (51.3) 76
Grade
well 2 (50) 2 (50) 4 0.138
moderate 55 (47) 62 (53) 117
poor 6 (85.7) 1 (14.3) 7
T status
T1+T2 16 (76.2) 5 (23.8) 21 0.007*
T3+T4 47 (43.9) 60 (56.1) 107
Lymph node metastasis
no 42 (56) 33 (44) 75 0.068
yes 21 (39.6) 32 (60.4) 53
Distant metastasis
no 56 (50.5) 55 (49.5) 111 0.476
yes 7 (41.2) 10 (58.8) 17
Stage
I 16 (80) 4 (20) 20 0.018*
II 22 (45.8) 26 (54.2) 48
III 20 (45.5) 24 (54.5) 44
IV 5 (31.3) 11 (68.8) 16
Stage
I/ II 38 (55.9) 30 (44.1) 68 0.108
III/IV 25 (41.7) 35 (58.3) 60
Overall survival
≤5 y 33 (44.6) 41 (55.4) 74 0.221
≥5 y 30 (55.6) 24 (44.4) 54
Data are shown as number of cases (%).
* significant at <0.05.
** significant at <0.005.
Table 2 Tumor nuclear CSE1L expression and clinical
parameters in CRC
Nuclear CSE1L Total P
Low (1+) High (2+ or 3+)
Sex
female 33 (63.5) # 19 (36.5) 52 0.099
male 37 (48.7) 39 (51.3) 76
Grade
well 3 (75) 1 (25) 4 0.699
moderate 63 (53.8) 54 (46.2) 117
poor 4 (57.1) 3 (42.9) 7
T status
T1+T2 13 (61.9) 8 (38.1) 21 0.467
T3+T4 57 (53.3) 50 (46.7) 107
Lymph node metastasis
no 40 (53.3) 35 (46.7) 75 0.714
yes 30 (56.6) 23 (43.4) 53
Distance metastasis
no 62 (55.9) 49 (44.1) 111 0.497
yes 8 (47.1) 9 (52.9) 17
Stage
I 12 (60) 8 (40) 20 0.346
II 23 (47.9) 25 (52.1) 48
III 28 (63.6) 16 (36.4) 44
IV 7 (43.8) 9 (56.2) 16
Stage
I/ II 35 (51.5) 33 (48.5) 68 0.436
III/IV 35 (58.3) 25 (41.7) 60
Overall survival
≤5 y 39 (52.7) 35 (47.3) 74 0.579
≥5 y 31 (57.4) 23 (42.6) 54
Data are shown as number of cases (%).
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curative resection [23]. Approximately 10% to 30% of
patients with stage II disease have experienced recur-
rence of this cancer [24]. Early detection and treatment
of colonic adenomas and early-stage CRC can signifi-
cantly reduce the incidence and mortality rate of CRC
[25]. Several studies have shown that the use of biomar-
kers is a valuable aid to the diagnosis and prognosis of
this disease, and enhances decision-making about treat-
ment [26-28]. Our data showed that CSE1L was posi-
tively stained (1+ to 3+) in most of the colorectal
carcinomas (99.2%), whereas the non-neoplastic colorec-
tal glands showed relatively low (±) CSE1L staining.
Therefore, CSE1L may be a useful immunohistochemical
marker for the detection and diagnosis of CRC.This study showed that CSE1L overexpression was asso-
ciated with increased invasion and metastasis in B16F10
melanoma cells, COLO 205 human CRC cells, and HT-29
human CRC cells (Figure 1). We had reported previously
that CSE1L overexpression in HT-29 human CRC cells sti-
mulated the polarity of these cells and inhibited their mi-
gration [16,29]. These results contradict the findings of the
current study, in which CSE1L expression was associated
with increased invasion and metastasis of tumor cells.
However, the HT-29 cell line appears to be unusual. In our
previous studies on CSE1L expression in other cancer cells,
CSE1L overexpression did not stimulate the polarity of
various cell lines, including B16F10 melanoma cells and
MCF-7 breast cancer cells [15,30]. Furthermore, CSE1L
overexpression did not inhibit the tumorigenicity of
these cells [15,30]. Overexpression of CSE1L in B16F10
Figure 4 Overall survival of colorectal cancer patients in relation to CSE1L expression. Kaplan-Meier curves for the overall survival of
patients with CRC, in relation to the degree of cytoplasmic (A) and nuclear (B) CSE1L immunohistochemical staining. Verticals marks indicate
censored events.
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invadopodia extension and matrix metalloproteinase-2
(MMP-2) secretion and increased the migration and
invasiveness of the cancer cells [15,30]. Similarly, CSE1L
overexpression in COLO 205 colon cancer cell line was
associated with an increase in the invasive ability of the
cells (Figure 1). The HT-29 human CRC cell line is a
special cell line that readily develops polarity in an
in vitro cell culture [31]. Thus, the association between
CSE1L overexpression and the development of polarity
and tumorigenicity inhibition observed in HT-29 cancer
cells appears to be specific to that cell line. We cannot
exclude the possibility that CSE1L may play a role in
polarity formation during embryo development [32]. In
the animal liver metastasis model, although the tumor
lesions induced by HT-29-CSE1L cells were obviously
smaller than that tumor lesions induced by HT-29-EVTable 3 Survival of CRC patients displaying high CSE1L
cytoplasmic expression in tumor
Univariate Model#
Variable Hazard ratio 95% CI P
Cytoplasmic CSE1L
Low 1 0.9 to 1.9 0.198
high 1.3
T status
T1+T2 1 1.4 to 3.5 <0.001***
T3+T4 2.2
Lymph node metastasis
no 1 1.3 to 2.4 <0.001***
yes 1.7
Stage
I/ II 1 1.3 to 2.5 <0.001***
III,IV 1.8
#Cox proportional hazard model.
*** significant at < 0.001.cells, reflecting the lower proliferation rate of HT-29-
CSE1L cells due to the induction of cell polarity by CSE1L
in HT-29 cells [16]. Nevertheless, the data showed that
enhanced CSE1L expression increased the in vivo metasta-
sis of HT-29 colon cancer cells to the livers of the SCID
mice (Figure 1C). The results indicate that CSE1L plays a
role in regulating the metastasis of colorectal cancer cells.
Moreover, CSE1L is known to stimulate the extension of
invadopodia and the secretion of matrix metalloproteinases
of several cancer cell lines [15,33]. Thus, stimulation of
tumor invasion and metastasis should be the correct role
of CSE1L in tumor development.
Our results also showed that in cases of CRC display-
ing high CSE1L cytoplasmic staining, the degree of
staining was associated with the T status and disease
stage. Tumor stage is significantly associated with clin-
ical outcomes in CRC patients, and the 5-y survival rate
decreases as the stage advances. Most deaths from CRC
are directly related to an advanced stage of the disease
[34,35]. Our results showed that although high cytoplas-
mic CSE1L staining in colorectal tumors was associated
with a lower overall survival rate compared with cases
displaying low cytoplasmic CSE1L expression, the differ-
ence was not statistically significant (Figure 4). Alnabulsi
et al. reported that CSE1L expression was related to the
occurrence of lymph node metastasis and the overall
survival rate of patients with CRC [36]. Their survival
analysis showed that early-stage colorectal cancer
patients whose tumors showed high CSE1L cytoplasmic
expression experienced poor survival outcomes [36].
The inconsistency in our results might be attributable to
the problems in staging CRC accurately using the
current evaluation methods, especially in the early stage
where occult metastasis may occur. Lymphatic invasion
in malignant polyps of the colon and rectum was
reported to be associated with an increased risk of re-
gional lymph node metastases [37]. Similarly, venous in-
vasion in colorectal carcinoma was recognized as a risk
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lationship between CSE1L expression and tumor cell
lymphatic vessel invasion and blood vessel invasion,
using 60 whole-mount sections of CRC specimens with
antibodies against the D2-40 lymphatic endothelial mar-
ker and the CD31 blood vessel endothelial marker. The
results showed that lymphatic or blood vessel invasion
was present in sixteen cases (26.6%), but there was no
statistic correlation between CSE1L expression and
tumor cell lymphatic vessel invasion and blood vessel in-
vasion (data not shown). However, at present there are
still many problems in the assay of lymphatic and blood
vessel invasion in CRC, such as the variability in recog-
nition, diagnosis, and reporting of lymphovascular inva-
sion, as well as in processing of specimens [39]. For
example, the result from a single focus on a single slide
is insufficient to confirm the absence of lymphovascular
invasion in a tumor. Therefore, the relationship between
CSE1L expression and colorectal cancer lymphatic and
blood vessel invasion still need to be investigated.
As mentioned, cytoplasmic CSE1L is associated with
the development of microtubules, and this association
may stimulate invadopodia extension and may enhance
the migration of tumor cells [15]. Previous studies on
cancer cells showed that CSE1L was colocalized with
MMP-2 in cytoplasmic areas near the cell membranes
and invadopodia, and that CSE1L overexpression
enhanced MMP-2 secretion and the invasive ability of
cancer cells [15,40,41]. Furthermore, a reduction in
CSE1L expression inhibited the metastasis of tumor cells
in animal models [15,40,41]. Microvesicles are rich in
metastasis-related proteases and play a role in the inter-
action between tumor cells and the tumor microenviron-
ment during metastasis [42]. A recent report on B16F10
melanoma cells showed that CSE1L overexpression trig-
gered microvesicle generation, whereas CSE1L knockdown
diminished Ras-induced microvesicle generation, MMP-2/
MMP-9 secretion, and metastasis [33]. Recent studies have
proposed that secretory CSE1L might be a potential prog-
nostic marker of cancer [33,40,41,43]. This study further
showed that cytoplasmic CSE1L was involved in the inva-
siveness of CRC cells. Thus, analysis of the cytoplasmic
distribution of CSE1L might provide a valuable tool for
diagnosing CRC and determining the prognosis.
Conclusion
This study showed that for patients with CRC, cytoplas-
mic CSE1L expression in neoplastic colorectal glands
correlated with depth of tumor penetration and cancer
stage. Analysis of the nuclear and cytoplasmic distribu-
tion of CSE1L in colorectal tumors might provide valu-
able clinical-pathological information to aid physicians
in making decisions about treatment. Ultimately, this
could reduce the mortality from the disease.Abbreviations
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